Pharmacy Service, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, Doctor Esquerdo, 46, 28007, Madrid, Spain.
Department of Cardiology, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain.
BMC Pulm Med. 2021 Feb 2;21(1):48. doi: 10.1186/s12890-021-01416-7.
Patients with pulmonary hypertension (PH) have progressive and disabling symptoms, as well as a burden of treatments and a difficult clinical evaluation that make health-related quality of life a particularly relevant endpoint in this disease. The objective of the study was to evaluate patient-reported outcomes of patients receiving specific treatment for PH in a tertiary hospital using a specific questionnaire (Cambridge Pulmonary Hypertension Outcome Review-CAMPHOR) in the pharmacy consultation.
A cross-sectional, observational, descriptive study was conducted. It included all patients receiving specific treatment for PH in a tertiary hospital in Madrid, Spain. The inclusion period comprised between August to December 2019. CAMPHOR questionnaires containing three domains: symptoms, activities and quality of life were completed by the patients at the pharmacy consultation. Demographic and clinical variables, including WHO Functional Class (WHO FC), PH-specific tests and hemodynamic parameters, were recorded. Non-parametric analyses to assess relations between variables and CAMPHOR domains were performed.
Thirty-six patients consented to participate in the study and completed the questionnaire. Median scores for symptoms, activities, and quality of life domains were 5.5 (2.5-10), 8.0 (4.5-10.5) and 3.5 (1-7.5), respectively. Statistically significant differences were found in the three domains when comparing by WHO FC, in the activities domain for 6-m walking test and in the quality of life domain for patients who had emergency visits or hospitalizations in the last year.
The CAMPHOR questionnaire could be useful as a complementary test to achieve an integrated evaluation of PH patients, who could complete it easily during their routine pharmacy visits.
患有肺动脉高压（PH）的患者会出现进行性和致残性症状，并且治疗负担沉重，临床评估困难，这使得健康相关生活质量成为该疾病的一个特别相关的终点。本研究的目的是使用特定问卷（剑桥肺高血压结局综述-CAMPHOR）在药房咨询中评估在三级医院接受特定 PH 治疗的患者的患者报告结局。
这是一项横断面、观察性、描述性研究。它包括在西班牙马德里的一家三级医院接受特定 PH 治疗的所有患者。纳入期为 2019 年 8 月至 12 月。CAMPHOR 问卷包含三个领域：症状、活动和生活质量，患者在药房咨询时填写。记录人口统计学和临床变量，包括世界卫生组织功能分类（WHO FC）、PH 特异性检查和血流动力学参数。进行非参数分析以评估变量与 CAMPHOR 领域之间的关系。
36 名患者同意参与研究并完成了问卷。症状、活动和生活质量领域的中位数评分为 5.5（2.5-10）、8.0（4.5-10.5）和 3.5（1-7.5）。在比较 WHO FC 时，三个领域均存在统计学显著差异，在 6 分钟步行试验中，活动领域存在差异，在过去一年中有急诊就诊或住院的患者中，生活质量领域存在差异。
CAMPHOR 问卷可作为 PH 患者综合评估的补充测试，患者在常规药房就诊时可轻松完成。
